ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO096

Atorvastatin vs. Rosuvastatin for Contrast-Induced Nephropathy Prevention in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials and Propensity-Score Matching

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Leelaviwat, Natnicha, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Mekraksakit, Poemlarp, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Del Rio-Pertuz, Gaspar, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Benjanuwattra, Juthipong, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Trongtorsak, Angkawipa, AMITA Health, Chicago, Illinois, United States
  • Duangkham, Samapon, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
  • Abdelnabi, Mahmoud, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
Background

Statins have been reported to prevent contrast-induced nephropathy (CIN) via various mechanisms. However, the studies that compare the effect between atorvastatin and rosuvastatin following percutaneous coronary intervention (PCI) are still lacking. We conducted a systematic review and meta-analysis to compare atorvastatin and rosuvastatin for the prevention of CIN in patients with acute coronary syndrome (ACS) undergoing PCI.

Methods

Two investigators independently searched the databases of MEDLINE and EMBASE from inception to April 28, 2022. We included randomized clinical trials (RCTs) and propensity-score-matched (PSM) studies that compared atorvastatin and rosuvastatin and the effect on CIN in patients with ACS undergoing PCI. Data from each study were combined using the random-effects model and the generic inverse-variance method.

Results

Six studies (5 RCTs and 1 PSM study) involving 2,690 patients with ACS from October 2013 to August 2020 were included in our meta-analysis. There was no statical difference between atorvastatin and rosuvastatin in preventing CIN (OR 1.2; 95% CI 0.89,1.61; I2 = 0%). However, the use of high-dose atorvastatin was associated with a decreased risk of CIN following PCI in ACS patients compared to low-dose atorvastatin (OR 0.5; 95% CI 0.29, 0.87; I2 = 0%).

Conclusion

Our meta-analysis indicated that the rate of CIN in patients with ACS undergoing PCI who received atorvastatin is not statistically different from those receiving rosuvastatin. Larger studies are needed to clarify this outcome.